Comparing Two Vitamin D3 Supplementation Plans in Early Pregnancy to Reduce Preeclampsia Risk Among Vitamin D Deficient Women

What this Trial Is About

Researchers are evaluating two different vitamin D3 supplementation plans during early pregnancy to see how they affect the risk of preeclampsia in women with vitamin D deficiency. This study is a randomized controlled trial conducted at Al-Thawra Modern General Hospital in Sanaa, Yemen, focusing on pregnant women with confirmed vitamin D deficiency between 8 and 18 weeks of gestation. Participants will be randomly assigned to one of two groups one group will receive 50,000 IU of vitamin D3 every two weeks, and the other will receive 5,000 IU weekly. Both groups will continue supplementation until delivery alongside their standard antenatal care. The study aims to compare the impact of these dosing schedules on reducing preeclampsia risk and other maternal and neonatal outcomes. Throughout the pregnancy, women will be monitored for the development of preeclampsia and other health outcomes for both mother and baby. Researchers will assess the incidence and severity of preeclampsia, gestational diabetes, hypertension, birth weight, preterm birth, and neonatal health measures. The study will follow participants from enrollment until delivery, and maternal mortality will be tracked up to 42 days postpartum, with neonatal outcomes observed until 28 days after birth.

Vitamin D3 Supplementation Regimens and Preeclampsia Risk